SAN FRANCISCO — A California-led Pillsbury team represented medical genetics testing company Invitae on an agreement to buy ArcherDX for up to $1.4 billion — creating a global leader in comprehensive cancer genetics and precision oncology.
Pillsbury has worked with Invitae since its formation in 2010 — including half a dozen pre-IPO private financings, the IPO, various financings and credit facilities as a public company and almost a dozen completed acquisitions.
The ArcherDX deal is the largest in a string of deals for Invitae, which last year acquired Singular Bio, Jungla and Clear Genetics. This year, Invitae has acquired Diploid, YouScript and Genelex.
The Pillsbury team was led by California-based Corporate partners Mike Hird, Gabriela Lombardi, Jason Stirling, Richard Blaylock and Alicia McKnight; and included Drew Simon-Rooke, Patrick Klingborg, Stephen Amdur, Mark Jones, Ena Kaur, Mustapha Parekh, C. Brian Wainwright, Julie Park, Charmaine Lindley, Jasmine Alves, Harriet McCartin, Mel Pudig, Ricky Lin, Laura Watts, Walker Force, Jeff Sheriff, Christopher Stretch, Catherine Meyer, Michelle Mehok, Alvin Dunn, Andrea Milano, Wayne Whitlock, Richard Nielsen, Evan Hamme, William Bennett and Matthew Rabinowitz.